Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Convertible Debt (2023)

Mereo BioPharma (MREO) has disclosed Convertible Debt for 1 consecutive years, with $4.4 million as the latest value for Q4 2023.

  • Quarterly Convertible Debt changed N/A to $4.4 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2023, changed N/A year-over-year, with the annual reading at $4.4 million for FY2023, N/A changed from the prior year.
  • Convertible Debt for Q4 2023 was $4.4 million at Mereo BioPharma.
  • The five-year high for Convertible Debt was $4.4 million in Q4 2023, with the low at $4.4 million in Q4 2023.